Legend Biotech, a subsidiary of GenScript Biotech Corporation, is set to present new data on its CARVYKTI® therapy for patients with multiple myeloma at two major upcoming medical conferences. The data, part of the CARTITUDE Clinical Development Program, will be showcased at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association's (EHA) Congress. Legend Biotech, whose shares are listed on the Nasdaq Global Select Market, made this announcement following a Form 6-K filing with the United States Securities and Exchange Commission. For more detailed information, interested parties are encouraged to visit Legend Biotech's official website.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.